Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00039026 · ClinicalTrials.gov registry record · Phase 3

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

A Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
377
Enrollment target
20
Study locations

NCT00039026 is a Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent that has completed, run by AstraZeneca. The registered enrollment target is 377 participants, above the 169-participant average among 5 other Diabetes Mellitus, Non-Insulin-Dependent trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00039026, a Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
377 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.

Conditions Studied

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

  • DRUG Placebo
  • DRUG AC2993

Study Locations (20)

Alabama

  • Pinnacle Research Group - Anniston
  • Parkway Medical Center - Birmingham
  • Alabama Clinical Therapeutics - Birmingham
  • Eclectic Family Care - Eclectic
  • Winston Physician Services - Haleyville
  • Simon Williamson Clinic - Hueytown
  • Extended Arm Physicians/ Southern Drug - Montgomery
  • Southern Drug Research Network - Tallassee

Arizona

  • Clinic of Physicians and Surgeons, Ltd. - Mesa
  • ANA Ventures, LLC - Mesa
  • Lovelace Scientific Resources-Phoenix - Phoenix
  • Physicians at the Peak - Phoenix
  • Advanced Clinical Therapeutics - Tucson

California

  • Advanced Clinical Research Institute - Anaheim
  • Mitchell Research Group, Inc. - Bakersfield
  • William Zigrang, M.D. - Burlingame
  • International Clinical Research Network - Chula Vista
  • Arrowhead Regional Medical Center - Colton

Arkansas

  • CAVHS - Little Rock
  • Physicians Group Research Clinic, LLC - Little Rock

Trial Details

FieldValue
Enrollment Target 377 participants
Start Date 2002-02
Est. Completion 2003-08
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00039026

The ClinicalTrials.gov registry entry for NCT00039026 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 169-participant average among 5 other Diabetes Mellitus, Non-Insulin-Dependent trials with a reported enrollment target (123% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Non-Insulin-Dependent appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00039026 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT00039026 about?

NCT00039026 is a clinical study titled "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea". This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their requ...

What is the current status of trial NCT00039026?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2002-02. Estimated completion is 2003-08.

What conditions does trial NCT00039026 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Non-Insulin-Dependent.

What interventions are being tested in trial NCT00039026?

The interventions under investigation include: Placebo (DRUG), AC2993 (DRUG).

Who is sponsoring clinical trial NCT00039026?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00039026 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Non-Insulin-Dependent

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Non-Insulin-Dependent

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.